Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADI) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 547,500 shares, an increase of 136.0% from the December 15th total of 232,000 shares. Based on an average trading volume of 322,600 shares, the days-to-cover ratio is currently 1.7 days. Approximately 2.7% of the shares of the company are short sold.

Aadi Bioscience Price Performance

NASDAQ:AADI opened at $2.99 on Wednesday. The company has a market cap of $73.69 million, a P/E ratio of -1.31 and a beta of 0.65. The stock’s fifty day moving average price is $2.63 and its two-hundred day moving average price is $2.05. Aadi Bioscience has a 1 year low of $1.21 and a 1 year high of $3.81.

Aadi Bioscience (NASDAQ:AADI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) EPS for the quarter, meeting the consensus estimate of ($0.46). Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. The company had revenue of $7.21 million during the quarter, compared to analysts’ expectations of $6.55 million. During the same quarter in the previous year, the company earned ($0.60) earnings per share. On average, analysts expect that Aadi Bioscience will post -1.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aadi Bioscience

Institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in shares of Aadi Bioscience in the 3rd quarter worth approximately $32,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Aadi Bioscience in the 2nd quarter worth $37,000. Finally, BML Capital Management LLC bought a new stake in Aadi Bioscience in the third quarter worth $4,120,000. 52.08% of the stock is currently owned by institutional investors.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.